ARN-509

目录号: GC16840纯度: >99.50%同义词: 阿帕鲁胺,ARN 509; ARN509, Apalutamide

ARN-509是一种合成的双芳基硫代乙内酰脲化合物，抑制雄激素受体（AR），IC₅₀值为16nM。

Cas No.: 956104-40-8

规格	价格	库存	数量
5mg	¥578.00	现货	1
10mg	¥998.00	现货	1
50mg	¥2,636.00	现货	1
10mM (in 1mL DMSO)	¥746.00	现货	1

电话: 400-920-5774Email: sales@glpbio.cn

文献被引

本产品暂无引用记录;以下为 GlpBio 产品在 Nature / Cell / Science 等顶刊的客户引用样例

Nature
641, 529–536 (2025)
Nature
628, 630–638 (2024)
Nature
632, 686–694 (2024)
Nature
618, 1017–1023 (2023)
Nature
610, 366–372 (2022)
Cell
187(9):2288-2304 (2024)
Cell
183(7):1867-1883 (2020)
Science
388(6745) (2025)
Science
387(6739) (2025)
Science
387(6734) (2025)
Cell Research
35, 97–116 (2025)
Cell Research
34, 683–706 (2024)
Cell Research
33, 273–287 (2023)
Cell Research
33, 546–561 (2023)
Cell Research
33, 904–922 (2023)
Cell Research
31, 1291–1307 (2021)

产品描述 Description

ARN-509 is a synthetic biaryl thiohydantoin compound that inhibits androgen receptor (AR), with an IC₅₀ value of 16nM^[1]. ARN-509 irreversibly binds to the ligand binding domain of the AR with high affinity, induces conformational changes in AR, hinders the translocation of the receptor complex to the nucleus, and thereby prevents its binding to androgen response elements^[2]. ARN-509 has been widely used in the related research on prostate cancer treatment^[3].

In vitro, ARN-509 treatment (100μM; 24h) significantly inhibited the proliferation of 22Rv1 cells, and suppressed nuclear entry of AR, AR-V7, and phosphorylated AR^[4]. Treatment with 10μM ARN-509 significantly inhibited AR signal transduction in LNCaP prostate cancer cell lines, resulting in reduced cell proliferation^[1].

In vivo, ARN-509 treatment through oral gavage at a dose of 30mg/kg/day for 60 weeks, which significantly reduced the incidence of prostate cancer induced by N-methyl-N-nitrosourea in male Wistar rats^[5]. In the LNCaP/AR castration-resistant prostate cancer (CRPC) mouse model, an oral administration dose of 10mg/kg/day of ARN-509 can significantly inhibit tumor regression^[6]. In genetically engineered mouse prostate cancer (GEM-PCa) models, four weeks of oral treatment with ARN-509 (30mg/kg/day) significantly reduced tumor burden by 33.5% and increased PI3K-AKT signaling^[7].

References:
[1]Clegg N J, Wongvipat J, Joseph J D, et al. ARN-509: a novel antiandrogen for prostate cancer treatment[J]. Cancer research, 2012, 72(6): 1494-1503.
[2]Smith M R, Antonarakis E S, Ryan C J, et al. Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort[J]. European urology, 2016, 70(6): 963-970.
[3]Smith M R, Antonarakis E S, Ryan C J, et al. ARN-509 in men with high risk non-metastatic castration-resistant prostate cancer[J]. Annals of Oncology, 2012, 23: ix303.
[4]Koukourakis M I, Kakouratos C, Kalamida D, et al. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines[J]. Anti-cancer drugs, 2018, 29(4): 323-333.
[5]Murillo G, Peng X, Muzzio M, et al. Exceptional activity of ARN-509 (apalutamide) in prostate cancer prevention in rats[J]. Cancer Research, 2019, 79(13_Supplement): 2730-2730.
[6]Hager J H, Smith N D, Bischoff E, et al. Effect of the novel anti-androgen ARN-509 on response and seizure in castration-resistant prostate cancer models[J]. Journal of Clinical Oncology, 2011, 29(7_suppl): 28-28.
[7]Velasco M A D, Nozawa M, Kura Y, et al. Apalutamide (ARN-509) demonstrates therapeutic efficacy in genetically engineered mouse models of Pten-deficient prostate cancer[J]. Cancer Research, 2018, 78(13_Supplement): 3737-3737.

ARN-509是一种合成的双芳基硫代乙内酰脲化合物，抑制雄激素受体（AR），IC₅₀值为16nM^[1]。ARN-509通过高亲和力不可逆地结合AR的配体结合域，诱导受体构象变化，阻碍受体复合物向细胞核的转运，从而阻止AR与雄激素反应元件的结合^[2]。ARN-509已被广泛应用于前列腺癌治疗的相关研究中^[3]。

在体外，ARN-509（100μM；24小时）处理能显著抑制22Rv1细胞的增殖，并阻断AR、AR-V7变体及磷酸化AR的核内转移^[4]。10μM浓度的ARN-509处理可显著抑制LNCaP前列腺癌细胞系的AR信号传导，导致细胞增殖减少^[1]。

在体内，ARN-509通过口服灌胃给药（30mg/kg/day)持续60周能显著降低雄性Wistar大鼠由N-甲基-N-亚硝基脲诱导的前列腺癌发生率^[5]。在LNCaP/AR去势抵抗性前列腺癌（CRPC）小鼠模型中，每日10mg/kg剂量的ARN-509口服给药可显著抑制肿瘤进展^[6]。在基因工程小鼠前列腺癌（GEM-PCa）模型中，ARN-509口服治疗（30mg/kg/day）持续4周，使肿瘤负荷显著降低33.5%，同时增强PI3K-AKT信号通路活性^[7]。

实验参考方法 Experimental Reference Method

Cell experiment [1]:
Cell lines	22Rv1 cells
Preparation Method	2.5×10³22Rv1 cells were inoculated in each well on a 96-well plate and incubated for 24 hours to allow the cells to attach to the well surface. Then, the cells were exposed to ARN-509 (10, 50, and 100μM; 24h) and Testosterone (10μmol/L; 24h). The effects on cell viability were tested when the ARN-509 and Testosterone were continuously present in the culture medium. To assess cell viability, 10%v/v AlamarBlue was added to each well. As a negative control (background measurement), ARN-509 was not contained in the culture medium. Vitamin C (5μl/well) was used as the positive control to completely reduce rizulin. Seven hours later, the relative fluorescence (in RFU: fluorescence per well minus background fluorescence) was measured using the microplate reader. Measure every other day from day 0 (24 hours after sowing) to day 6. The experiments were conducted under normal hypoxia and 1% hypoxia conditions.
Reaction Conditions	10, 50, and 100μM; 24h
Applications	ARN-509 significantly inhibited the viability of 22Rv1 cells in a dose-dependent manner.
Animal experiment [2]:
Animal models	SHO male mice
Preparation Method	The in vivo xenotransplantation experiment was conducted in male SHO mice. Mice had their testicles removed under isoflurane anesthesia and were given a recovery time of 7 to 10 days. LNCaP/AR (cs) cells were suspended in 50% RPMI and 50% Matrigel. 3×10⁶ cells were injected into each xenograft, with a volume of 100μL. Observe the animals every week until the tumor grows significantly. Forty to 60 days after injection, the animals were randomly divided into cohorts with equal average tumor burden and range (150-250mm³). In all LNCaP/AR (cs) xenotransplantation studies, ARN-509 (30mg/kg) and enzalutamide active pharmaceutical ingredients were prepared in 18% PEG-400, 1% Tween-80 and 1% povidone, and in 15% vitamin E-TPGS and 65% 0.5% w/v CMC solution, all compounds were administered by oral gavage daily. After daily administration of ARN-509 for 60 days, the tumor growth in mice was analyzed.
Dosage form	30mg/kg/day for 60 days; p.o.
Applications	ARN-509 treatment significantly suppressed tumor growth, and increased the survival rate of mice.
References: [1]Koukourakis M I, Kakouratos C, Kalamida D, et al. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines[J]. Anti-cancer drugs, 2018, 29(4): 323-333. [2]Joseph J D, Lu N, Qian J, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509[J]. Cancer discovery, 2013, 3(9): 1020-1029.

产品文档 Product Documents

Purity:>99.50%

化学性质Chemical Properties

CAS 号

956104-40-8

同义词

阿帕鲁胺,ARN 509; ARN509, Apalutamide

化学名

4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide

SMILES

CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CN=C(C(=C4)C(F)(F)F)C#N)F

分子式

C₂₁H₁₅F₄N₅O₂S

分子量

477.43 g/mol

溶解性

≥ 23.85mg/mL in DMSO

保存条件

Store at -20°C

General tips

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
为了提高溶解度，请将管子加热至 37°C，然后在超声波浴中震荡一段时间。

Shipping Condition

评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备 RT，或根据请求配备蓝冰。

计算工具摩尔浓度 / 稀释 / 分子量 / 单位换算 / 体内配方 / 溶解度

质量 (Mass)

体积 (Volume)

浓度 (Concentration)

分子量 (MW)

g/mol